Answers are grounded in this paper and cite their sources.
Background: In the MONALEESA-3 trial (NCT02422615), ribociclib + fulvestrant significantly improved progression-free survival (PFS) vs placebo + fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative BC who had received no or only 1line of prior endocrine therapy for ABC. Here, we present PROs from the trial, including health-related quality of life (HRQoL).
No takes yet. Share an insight, caveat, or question.
Fasching et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: